Emcure Pharmaceuticals has seen a steady 18% increase in earnings per share (EPS) over the past three years, boosted by revenue growth of 17% to ₹92 billion. The company's insiders hold 70% ownership, suggesting confidence in its future growth. Its stable EBIT margins and high EPS growth make it an attractive investment option.

Emcure Pharma's Sanand facility received a Form 483 from the US FDA, citing seven procedural issues, not related to product quality. The company is working diligently to address these observations as per the set timeline.

Emcure Pharmaceuticals reported a significant 16.6% increase in revenue for the fiscal year 2026, reaching Rs.9,204 crores. The company aims to concentrate on improving its EBITDA growth moving forward.

Emcure Pharmaceuticals announces a proposed dividend of Rs. 3.60 per share for fiscal year 2026, subject to approval at the upcoming AGM. Notably, Dr. Mukund Gurjar and Satish Mehta have been appointed as Whole-time Director and Managing Director, respectively, for extended terms.

Bain Capital has offloaded a 0.95% share in Emcure Pharma for INR 289.5 crore, causing Emcure shares to dip by 2.3%. The stake was purchased by Norway's Pension Fund.

Emcure Pharmaceuticals' board will convene on May 5, 2026, to review and approve their audited financial results for the year. The meeting will also discuss the potential declaration of a final dividend. Trading activity for the company has been suspended from May 5th to May 7th, 2026.

Emcure Pharma experienced a significant block trade worth approximately INR 98 crore on NSE, involving around 614,310 shares and priced at INR 1600.6 each.

Emcure Pharma's subsidiary, Mantra Pharma, has purchased Cutimed Inc. for CAD 5.05M, bolstering their Canadian dermatology and cosmetics offerings by merging with the Canadian company.